Lipid-lowering Benefits of Alirocumab Extend to Patients With High-risk Diabetes

Key clinical point: The benefits of alirocumab seen in the main study population extend to people with diabetes, with no risk for new onset or worsening of diabetes.

Major finding: Mean placebo-corrected reductions in LDL cholesterol level at 24 weeks were –59.2% in people with and –63.3% in people without diabetes (P = .1155).

Data source: A randomized, double-blind placebo-controlled study of alirocumab or placebo added to existing lipid-lowering treatment in 2,341 individuals at high cardiovascular risk and hyperlipidemia despite receiving statin therapy, including 838 with diabetes.

Disclosures: Sanofi and Regeneron Pharmaceuticals funded the study. Dr. Colhoun disclosed acting as an advisory panel member for both companies as well as several other companies including Roche, of which she was also a stockholder or shareholder.